InterCure Corrects Private Placement Pricing to $4.71/Unit After Reverse Split
INCR sits 69% above its 52-week low of $3.4 on light trading volume (0.2× avg).
Summary
InterCure corrected the pricing terms of its $5.3 million private placement to reflect the 1-for-5 reverse split, with units now priced at $4.71 and warrants exercisable at $7.07.
Key Events · Financing and Capital Events · INCR
-
Pricing Correction After Reverse Split
The 6-K/A corrects the unit purchase price to $4.71 per unit and warrant exercise price to $7.07 per Ordinary Share, giving effect to the 1-for-5 reverse split effective August 24, 2026.
-
Gross Proceeds Clarified
Gross proceeds from the offering were $5.3 million, excluding CEO Alexander Rabinovich's expected $2.1 million participation, which remains subject to shareholder approval.
-
Offering Structure
The placement consists of 1,579,028 units, each comprising one Ordinary Share and one five-year warrant to purchase one Ordinary Share.
-
Use of Proceeds
Proceeds are intended for working capital and rehabilitation of the Nir Oz facility of wholly owned subsidiary Canndoc Ltd.
Analysis · INCR · Life Sciences
InterCure amended its August 26 filing to correct the unit price and warrant exercise price for its private placement, which had failed to reflect the 1-for-5 reverse split effective August 24. The corrected terms show a unit price of $4.71 and warrant exercise price of $7.07 — both post-split figures. Gross proceeds of $5.3 million exclude CEO Alexander Rabinovich's expected $2.1 million participation, which still requires shareholder approval. The correction matters because the previously reported $2.918 unit price understated the actual economics of the deal by a factor of five.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1594 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INCR was trading at $5.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $68M. The 52-week trading range was $3.40 to $8.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.